Compare CERT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERT | CTMX |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.9M | 977.1M |
| IPO Year | 2020 | 2015 |
| Metric | CERT | CTMX |
|---|---|---|
| Price | $6.33 | $3.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $11.67 | ★ $12.10 |
| AVG Volume (30 Days) | 2.5M | ★ 3.4M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $418,838,000.00 | $76,201,000.00 |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | $5.39 | $7.61 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $5.19 | $1.72 |
| 52 Week High | $13.88 | $8.21 |
| Indicator | CERT | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 36.51 |
| Support Level | $5.93 | $3.83 |
| Resistance Level | $6.48 | $3.91 |
| Average True Range (ATR) | 0.28 | 0.25 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 76.87 | 3.96 |
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.